KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanomaПодробнее

KEYNOTE-716: safety profile and results of pembrolizumab for melanomaПодробнее

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 studyПодробнее

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanomaПодробнее

KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanomaПодробнее

KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanomaПодробнее

KEYNOTE-716: long-term efficacy and safety of pembrolizumab in resected melanomaПодробнее

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanomaПодробнее

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022Подробнее

Final analysis of distant metastasis-free survival in the KEYNOTE-716 studyПодробнее

Dr. Weber on Adjuvant Pembrolizumab in MelanomaПодробнее

Long-Term Safety of Pembrolizumab for Advanced MelanomaПодробнее

Long-term efficacy of pembrolizumab in advanced melanomaПодробнее

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanomaПодробнее

Adjuvant therapy for high-risk melanomaПодробнее

Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...Подробнее

KEYNOTE-555: pembrolizumab bioavailability after subcutaneous administration in melanomaПодробнее

Melanoma highlights from ESMO 2021Подробнее